EIF3F-related neurodevelopmental disorder: refining the phenotypic and expanding the molecular spectrum.
Altered muscular tone
Behavioral difficulties
Deafness
EIF3F gene
Neurodevelopmental disorder
Short stature
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
18 03 2021
18 03 2021
Historique:
received:
10
12
2020
accepted:
15
02
2021
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
22
6
2021
Statut:
epublish
Résumé
An identical homozygous missense variant in EIF3F, identified through a large-scale genome-wide sequencing approach, was reported as causative in nine individuals with a neurodevelopmental disorder, characterized by variable intellectual disability, epilepsy, behavioral problems and sensorineural hearing-loss. To refine the phenotypic and molecular spectrum of EIF3F-related neurodevelopmental disorder, we examined independent patients. 21 patients were homozygous and one compound heterozygous for c.694T>G/p.(Phe232Val) in EIF3F. Haplotype analyses in 15 families suggested that c.694T>G/p.(Phe232Val) was a founder variant. All affected individuals had developmental delays including delayed speech development. About half of the affected individuals had behavioral problems, altered muscular tone, hearing loss, and short stature. Moreover, this study suggests that microcephaly, reduced sensitivity to pain, cleft lip/palate, gastrointestinal symptoms and ophthalmological symptoms are part of the phenotypic spectrum. Minor dysmorphic features were observed, although neither the individuals' facial nor general appearance were obviously distinctive. Symptoms in the compound heterozygous individual with an additional truncating variant were at the severe end of the spectrum in regard to motor milestones, speech delay, organic problems and pre- and postnatal growth of body and head, suggesting some genotype-phenotype correlation. Our study refines the phenotypic and expands the molecular spectrum of EIF3F-related syndromic neurodevelopmental disorder.
Sections du résumé
BACKGROUND
An identical homozygous missense variant in EIF3F, identified through a large-scale genome-wide sequencing approach, was reported as causative in nine individuals with a neurodevelopmental disorder, characterized by variable intellectual disability, epilepsy, behavioral problems and sensorineural hearing-loss. To refine the phenotypic and molecular spectrum of EIF3F-related neurodevelopmental disorder, we examined independent patients.
RESULTS
21 patients were homozygous and one compound heterozygous for c.694T>G/p.(Phe232Val) in EIF3F. Haplotype analyses in 15 families suggested that c.694T>G/p.(Phe232Val) was a founder variant. All affected individuals had developmental delays including delayed speech development. About half of the affected individuals had behavioral problems, altered muscular tone, hearing loss, and short stature. Moreover, this study suggests that microcephaly, reduced sensitivity to pain, cleft lip/palate, gastrointestinal symptoms and ophthalmological symptoms are part of the phenotypic spectrum. Minor dysmorphic features were observed, although neither the individuals' facial nor general appearance were obviously distinctive. Symptoms in the compound heterozygous individual with an additional truncating variant were at the severe end of the spectrum in regard to motor milestones, speech delay, organic problems and pre- and postnatal growth of body and head, suggesting some genotype-phenotype correlation.
CONCLUSIONS
Our study refines the phenotypic and expands the molecular spectrum of EIF3F-related syndromic neurodevelopmental disorder.
Identifiants
pubmed: 33736665
doi: 10.1186/s13023-021-01744-1
pii: 10.1186/s13023-021-01744-1
pmc: PMC7977188
doi:
Substances chimiques
EIF3F protein, human
0
Eukaryotic Initiation Factor-3
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
136Références
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
JAMA Neurol. 2019 Mar 1;76(3):342-350
pubmed: 30575854
J Invest Dermatol. 2009 Feb;129(2):355-8
pubmed: 18800148
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Am J Hum Genet. 2001 Apr;68(4):978-89
pubmed: 11254454
JAMA Psychiatry. 2017 Mar 1;74(3):293-299
pubmed: 28097321
Genet Med. 2018 Jun;20(6):630-638
pubmed: 29758562
J Physiol. 2019 Jun;597(12):3107-3131
pubmed: 31026345
Genet Med. 2020 May;22(5):878-888
pubmed: 31949314
Science. 2018 Dec 7;362(6419):1161-1164
pubmed: 30409806
Bioinformatics. 2005 Jan 15;21(2):263-5
pubmed: 15297300
Hum Mutat. 2015 Oct;36(10):928-30
pubmed: 26220891
EMBO J. 2007 Jul 25;26(14):3373-83
pubmed: 17581632
Nature. 2015 Jun 4;522(7554):111-4
pubmed: 25849773
Hum Genet. 2017 Nov;136(11-12):1419-1429
pubmed: 28940097